Potent genotoxic reagents such as mitoxantrone, docetaxel, hydrogen peroxide, bleomycin and radiation have recently been studied in PSC27 cell lines (Normal Human Prostate Stromal Cell Lines) and in breast cancer cell lines. prostate such as PC-3, LNCaP, DU145, BPH1 and M12 cells. These chemotherapy reagents are ultimately DNA-damaging mechanisms that break hydrogen bonds and DNA strands in DNA. There are major implications associated with the use of chemotherapeutic agents. Prostate cancer patients often undergo one to five of these key treatments. But recent studies have shown that 90% of patients with metastatic carcinomas experience some type of resistance, because these chemotherapy agents essentially induce overexpression of the WNT16B protein in PSC27 cells found in the areas surrounding the tumor. Once this expression has occurred significantly, it reduces the overall competence of chemotherapeutic agents and leads to their ineffectiveness. This is a big problem for the patient and for those who produce these chemotherapeutic agents. To test the expression of WNT16B protein, RT-PCR (reverse transcription polymerase chain reaction) analysis will be conducted for LNCaP and PC-3 cells treated with mitozantrone, docetaxel and hydrogen peroxide before and after the treatment process . Introduction Current research has profoundly indicated that there are negative implications associated with the use of chemotherapeutic agents among prostate cancer patients. The article recently published in 2012, entitled “Treatment-induced damage to the tumor microenvironment promotes prostate cancer resistance through WNT16B”, showed a clear analysis of how genotoxic reagents such as Mitoxantrone, Bleomycin, Docetax… in the middle of 'article... ....the toxicity of chemotherapeutic agents that induce the expression of the WNT16 gene can also have other negative consequences. The chemotherapy drug Mitoxantrone can cause debilitating health consequences, such as heart failure, and increase your chance of acute leukemia. The drug Docetaxel may promote cardiotoxicity or heart damage. The drug Bleomycin promotes pulmonary toxicity. These are some of the few negative consequences that these drugs can cause and are used by prostate cancer patients. There is a long list of side effects and high rates of mortality and resistance associated with the use of chemotherapeutic agents. Works CitedSun, Y., Campis, J., Higano, C., & Beer, T. (2012) . “Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B.” Nature Medicine. 18(9), 1–23.PDF